Literature DB >> 183644

Equine herpesviruses. 6. Sequential infection of horses with types 2, 3 and 1.

C R Wilks, M J Studdert.   

Abstract

The immunological and virological status of 3 foals in respect of equine herpesviruses (EHV) was established and the foals were sequentially infected with EHV2, EHV3 and EHV1. Following experimental infection with EHV2, no clinical signs of disease were observed in any foal. The inoculation of EHV3 into the genital tract resulted in lesions of the mucous membrane and perineal skin that were considered typical of equine coital exanthema. Following intransal inoculation of EHV3 extensive ulceration and pustule formation on the nasal mucosa was observed by day 5 accompanied at day 7 by a profuse, mucopurulent nasal discharge; on day 8 pustular lesions of the skin about the external nares appeared. Signs of disease after inoculation with EHV1 were milder than expected in 2 of the 3 foals. The possibility that recent, prior infection with EHV2 and/or 3 may protect against EHV1 was considered.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 183644     DOI: 10.1111/j.1751-0813.1976.tb00064.x

Source DB:  PubMed          Journal:  Aust Vet J        ISSN: 0005-0423            Impact factor:   1.281


  3 in total

1.  Antigenic relatedness of equine herpes virus types 1 and 3.

Authors:  D E Gutekunst; W A Malmquist; C S Becvar
Journal:  Arch Virol       Date:  1978       Impact factor: 2.574

2.  Isolation of equine herpesvirus 3 (EHV-3) from equine coital exanthema of two stallions and sero-epidemiology of EHV-3 infection in Japan.

Authors:  Rikio Kirisawa; Yuko Toishi; Ai Akamatsu; Kosuke Soejima; Taisuke Miyashita; Nobuo Tsunoda
Journal:  J Vet Med Sci       Date:  2017-01-27       Impact factor: 1.267

3.  Period of excretion of equine herpesvirus 3 (EHV-3) from a stallion before showing clinical signs of equine coital exanthema and the effect of acyclovir treatment on the duration of EHV-3 excretion.

Authors:  Yuko Toishi; Nobuo Tsunoda; Rikio Kirisawa
Journal:  J Vet Med Sci       Date:  2020-07-20       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.